CMPX Company Profile and Key Details

Compass Therapeutics, Inc. has 171.57 million shares outstanding. The public float is 100.80 million shares, elevated short interest at 9.65% of float. This equals 10.25 million shares. The short ratio is 7.6 days. Institutional investors hold 70.71% of the float. Insiders own 11.42%. OrbiMed Genesis GP LLC holds 14.69 million shares, Schuetz Thomas J. has 6.48 million shares and Sunderland Julie has 2.50 million shares.

Short-term trend indicators are bearishly aligned (SMA20 -4.64%, SMA50 6.96%, SMA200 58.89%). The stock’s 14-day RSI is 49.52 (neutral), while the ATR of 0.31 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -14.85% below its high and over 275.19% above its low. Average 10-day trading volume of 2.88 million shares is slightly above the 3-month average of 1.96 million, indicating heightened recent market interest.

Compass Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.31. This means the shares are trading above this model’s fair value.

Our AI price prediction model suggests that Compass Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.61%, with price expected at $4.81 by January 02, 2026, within a range of $4.58 to $5.01 3-Month Outlook: Projected rise of 174.95%, reaching $13.72 by March 19, 2026, with a range of $13.57 to $14.00. 1-Year Outlook: Projected gain of 522.04%, with price at $31.04 by December 18, 2026, within a range of $29.99 to $40.64.

Compass Therapeutics, Inc. trades at a P/E ratio of -10.49, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.29 trading at moderately above to book value. The P/FCF stands at -20.17, also below market averages.

Compass Therapeutics, Inc. (NASDAQ:CMPX) closed at $5.14 USD, gaining $0.15 (3.11%) from the previous close of $4.99. The stock is currently mid-range between its 52-week high and low $1.33 and $5.86. With a market capitalization of about $711.48 million, Compass Therapeutics, Inc. is classified as a small-cap and shows market-like volatility (beta ~1.25). Key stats such as the average daily volume over the past year has been around 1.96 million shares, volume is running light vs its 52-week average. Headquartered in Boston, MA, Compass Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Thomas J. Schuetz, the company employs approximately 35 people and listed since April 05, 2021. Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases.

Compass Therapeutics, Inc. generated EPS of -$0.46 over the past year. Five-year average earnings growth is -104.7%. Wall Street analysts project EPS growth of 2.04% annually over the next five years. The latest quarter delivered EPS of -$0.10. The next quarter is forecast at -$0.09. Next year's EPS is expected at -$32.62. Analyst sentiment is bullish. Analyst rating data shows there are 10 Strong Buy ratings, 15 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $32.00 to $6.00. The high target offers 541.28% upside. The low target suggests 20.24% downside. The mean target is $16.68. This offers 234.27% upside. Compass Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by -26.34%. The prior quarter beat by 7.69%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in August 12, 2024.

Compass Therapeutics, Inc. (NASDAQ:CMPX) shares are up 244.14% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Compass Therapeutics, Inc. trading at a premium to the broader market with a P/E of -10.49. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $13.69, suggesting 174.35% upside. Our AI forecast model points to short-term weakness (-3.61% over two weeks), a medium-term rise (174.95% over three months), and a longer-term gain (522.04% over one year), with expected trading ranges indicating moderate volatility.